Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Providence County
    4. ›
  4. Providence
    5. ›
  5. EpiVax, Inc.

EpiVax, Inc.

Company claim

Is this your business?

Get access!

Company Details

Name: EpiVax, Inc.
Jurisdiction: Rhode Island
Entity type: Domestic Profit Corporation
Status: Conversion
Date of Organization in Rhode Island: 18 May 1998 (27 years ago)
Date of Dissolution: 20 Dec 2024 (7 months ago)
Date of Status Change: 20 Dec 2024 (7 months ago)
Identification Number: 000100649
ZIP code: 02909
City: Providence
County: Providence County
Purpose: TO ENGAGE IN THE BUSINESS OF DEVELOPING VACCINE AND THERAPEAUTIC DRUG CANDIDATES AND RELATED RESEARCH AND DEVELOPMENT.
Principal Address: Google Maps Logo 188 VALLEY STREET SUITE 424, PROVIDENCE, RI, 02909, USA

Industry & Business Activity

NAICS

541714 Research and Development in Biotechnology (except Nanobiotechnology)

This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Learn more at the U.S. Census Bureau

Companies doing Research and development in biotechnology (except nanobiotechnology)

Agent

Name Role Address
ANNE S. DEGROOT Agent 188 VALLEY STREET SUITE 424, PROVIDENCE, RI, 02909, USA

PRESIDENT

Name Role Address
ANNE S DEGROOT PRESIDENT 188 VALLEY ST, STE 424 PROVIDENCE, RI 02909 USA

TREASURER

Name Role Address
ANNE S DEGROOT TREASURER 188 VALLEY ST, STE 424 PROVIDENCE, RI 02909 USA

SECRETARY

Name Role Address
ANNE S DEGROOT SECRETARY 188 VALLEY ST, STE 424 PROVIDENCE, RI 02909 USA

CIO

Name Role Address
WILLIAM MARTIN CIO 188 VALLEY ST, STE 424 PROVIDENCE, RI 02909 USA

COO

Name Role Address
RICHARD SCHABOWSKY COO 188 VALLEY ST, STE 424 PROVIDENCE, RI 02909 USA

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Phone Number:
401-272-2123
E-mail Address:
AnnieD@EpiVax.com
Fax Number:
401-272-4562
Contact Person:
ANNE DE GROOT
Ownership and Self-Certifications:
Women-Owned Small Business, Woman Owned
User ID:
P0705709
SBA Link:
View company profile on SBA website

Form 5500 Series

Employer Identification Number (EIN):
050499380
Plan Year:
2023
Number Of Participants:
60
Sponsor's telephone number:
4012722123
File:
View File
Plan Administrator / Signatory:
SARAH BOTELHO(Plan administrator)
SARAH BOTELHO(Employer/plan sponsor)
Plan Year:
2022
Number Of Participants:
48
Sponsor's telephone number:
4012722123
File:
View File
Plan Administrator / Signatory:
SARAH BOTELHO(Plan administrator)
Plan Year:
2021
Number Of Participants:
47
Sponsor's telephone number:
4012722123
File:
View File
Plan Administrator / Signatory:
SARAH BOTELHO(Plan administrator)
SARAH BOTELHO(Employer/plan sponsor)
Plan Year:
2020
Number Of Participants:
49
Plan Name:
401(K)
Sponsor's telephone number:
4012722123
File:
View File
Plan Administrator / Signatory:
SARAH BOTELHO(Plan administrator)
Plan Year:
2019
Number Of Participants:
42
Plan Name:
401(K)
Sponsor's telephone number:
4012722123
Plan Administrator / Signatory:
SBOTELHO9973(Plan administrator)

Filings

Number Name File Date
202445186170 Annual Report 2024-02-01
202327447690 Annual Report 2023-02-03
202208743680 Annual Report 2022-01-27
202191966350 Annual Report 2021-02-18
202032277300 Annual Report 2020-01-14

USAspending Awards / Contracts

Procurement Instrument Identifier:
75D30119P05312
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
$200,692
Base And Exercised Options Value:
$200,692
Base And All Options Value:
$200,692
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2019-08-15
Description:
BORDETELLA PERTUSSIS IMMUNOGENICITY PREDICTION
Naics Code:
541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Product Or Service Code:
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)
Procurement Instrument Identifier:
HHSF223201300971P
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
$20,561
Base And Exercised Options Value:
$20,561
Base And All Options Value:
$20,561
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2013-09-05
Description:
IGF::OT::IGF HUMAN LEUKOCYTE ANTIGENS (HLA)BINDING STUDY AND IN-VITRO CHARACTERIZATION OF EPITOPES.
Naics Code:
541711: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
Product Or Service Code:
B504: SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL
Procurement Instrument Identifier:
W81XWH09C0190
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
$158,128
Base And Exercised Options Value:
$158,128
Base And All Options Value:
$158,128
Awarding Agency Name:
Department of Defense
Performance Start Date:
2009-09-29
Description:
RESEARCH PEPTIDES TO HUMAN MCH ALLELES
Naics Code:
541990: ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES
Product Or Service Code:
AN91: OTHER MEDICAL (BASIC)

USAspending Awards / Financial Assistance

Business Type:
SMALL BUSINESS
Date:
2023-08-23
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
PA21259, SBIR, PHASE I, IMPROVING T CELL RESPONSES IN VACCINES: PREDICTION AND VALIDATION USING EXISTING DATABASES, IMMUNOINFORMATICS AND IN VITRO ASSAYS
Obligated Amount:
$299,930
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2023-07-27
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
VALIDATION AND IMPROVEMENT OF ISPRI-HCP: AN INNOVATIVE PLATFORM FOR IMMUNOGENICITY RISK ASSESSMENT OF PROCESS-RELATED PROTEIN IMPURITIES - ABSTRACT THE IDENTIFICATION AND REMOVAL OF PROCESS-RELATED PROTEIN IMPURITIES (PRPI) FROM BIOLOGIC PRODUCTS IS A CRITICAL STEP IN DRUG DEVELOPMENT. DESPITE RECENT IMPROVEMENTS IN THE PURIFICATION AND PROCESSING OF BIOLOGICS, THE PRESENCE OF IMMUNOGENIC PRPI CONTINUE TO RAISE CONCERNS ABOUT DRUG SAFETY AND EFFICACY. WE PROPOSE AN INNOVATIVE APPROACH FOR ASSESSING IMMUNOGENICITY RISK OF PRPI USING OUR EXISTING ISPRI-HCP PLATFORM. ISPRI- HCP STANDS APART FROM CONVENTIONAL METHODS BY UTILIZING A T CELL APPROACH BASED ON THE T CELL EPITOPE COUNT AND DENSITY. WE HYPOTHESIZE THAT ISPRI-HCP CAN ACCURATELY CLASSIFY CANDIDATE PRPI IMPURITIES ACCORDING TO THEIR IMMUNOGENICITY RISK. TO TEST THIS HYPOTHESIS, WE WILL DETERMINE THE T CELL IMMUNOGENICITY OF 8 FREQUENTLY FOUND PRPI FROM CHINESE HAMSTER OVARY (CHO) CELL EXPRESSION SYSTEMS AND 5 PRPI FROM ADENOVIRAL VACCINES. THE SELECTED PRPI CLASSIFIED BY ISPRI-HCP COVER A WIDE RANGE OF IMMUNOGENICITY RISK. PEPTIDE POOLS COMPRISED OF T CELL EPITOPES OF THE SELECTED PROTEINS WILL BE PREPARED AND TESTED FOR THEIR ABILITY TO INDUCE ANTIGEN-SPECIFIC INF-G SECRETING T CELLS IN ASSAYS USING PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS). THE OVERALL GOAL OF THIS STUDY IS TO PROVIDE PROOF-OF-CONCEPT AND FURTHER IMPROVE ISPRI-HCP AS A PLATFORM FOR PREDICTING THE IMMUNOGENICITY RISK OF PRPI.
Obligated Amount:
$299,917
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2022-08-24
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
ISPRI-HCP: CHO PROTEIN IMPURITY IMMUNOGENICITY RISK PREDICTION FOR IMPROVING BIOSIMILAR PRODUCT DEVELOPMENT AND ASSESSING PRODUCT INTERCHANGEABILITY - ABSTRACT THE IDENTIFICATION AND REMOVAL OF HOST CELL PROTEINS (HCP) FROM BIOLOGIC PRODUCTS IS A CRITICAL STEP IN BIOSIMILAR DRUG DEVELOPMENT. WHILE THE SEQUENCE OF A BIOSIMILAR MAY BE IDENTICAL TO THE INNOVATOR, THE PROCESS USED TO PRODUCE THE BIOSIMILAR WILL BE DIFFERENT, AND AS A RESULT, NEW HCPS MAY BE INTRODUCED INTO THE PRODUCT. DESPITE RECENT IMPROVEMENTS TO PURIFICATION PROCESSES, BIOLOGICS THAT ARE MANUFACTURED IN DIFFERENT CELL LINES AND PURIFIED USING DIFFERENT PROCESSES CONTAIN VARIABLE HCP IMPURITIES, MAKING IT NECESSARY TO IDENTIFY AND QUANTIFY IMPURITIES FOR EACH PRODUCT, BE IT A REFERENCE INNOVATOR PRODUCT OR A PROPOSED BIOSIMILAR PRODUCT. IN THIS U01 PROGRAM, WE PROPOSE TO DEVELOP A PREDICTIVE MODEL FOR HCP IMMUNOGENICITY THAT CAN FACILITATE ASSESSMENT OF CLINICALLY MEANINGFUL IMMUNOGENICITY RISK FOR BIOLOGICS AND ASSESS INTERCHANGEABILITY RISK BETWEEN A BIOSIMILAR AND AN INNOVATOR PRODUCT. WE HAVE DEVELOPED A WEB-BASED TOOL CALLED ISPRI-HCP (FORMERLY CALLED CHOPPI) THAT PREDICTS THE IMMUNOGENIC POTENTIAL OF HCP SEQUENCES BY EVALUATING T CELL EPITOPE COUNT AND DENSITY, AND RELATIVE CONSERVATION WITH OTHER EPITOPES IN THE HUMAN GENOME. BUILDING ON PREVIOUS STUDIES OF MONOCLONAL ANTIBODY AND BIOLOGIC PROTEIN IMMUNOGENICITY USING SILICO METHODS AND OUR FDA GENERIC PEPTIDE IMMUNOGENICITY RESEARCH EXPERIENCE, WE HYPOTHESIZE THAT ISPRI-HCP CAN ACCURATELY CLASSIFY CANDIDATE HCP IMPURITIES ACCORDING TO THEIR IMMUNOGENICITY RISK. TO ADDRESS THIS HYPOTHESIS, WE WILL TRAIN, TEST AND CROSS-VALIDATE AN IMMUNOGENICITY PREDICTION MODEL FOR CHINESE HAMSTER OVARY (CHO) HCPS USING A T CELL IMMUNOGENICITY DATASET GENERATED FOR 87 COMMON CHO HCP IMPURITIES IN LICENSED MONOCLONAL ANTIBODY PRODUCTS WITH OUR METHOD FOR STIMULATING DE NOVO T CELL RESPONSES IN VITRO, NAMED IN VITRO IMMUNIZATION PROTOCOL (AIM 1). WE WILL ALSO TEST THE QUALITY OF THE ANTIGEN STIMULATION STRATEGY THAT IS USED TO STIMULATE DE NOVO T CELL IMMUNOGENICITY DATA FOR DEVELOPMENT OF THE ISPRI-HCP PREDICTIVE MODEL (AIM 2). THIS RESEARCH PROGRAM WILL IMPROVE THE ACCURACY OF THE ISPRI-HCP PLATFORM, PROVIDING DRUG DEVELOPERS WITH A RAPID AND EFFICIENT MEANS TO REDUCE HCP-ASSOCIATED IMMUNOGENICITY RISK TO ADDRESS THIS CRITICAL QUALITY ATTRIBUTE IN BIOSIMILAR DEVELOPMENT.
Obligated Amount:
$1,999,984
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2020-04-07
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
$0
Face Value Of Loan:
$447,000
Total Face Value Of Loan:
$562,000
Business Type:
SMALL BUSINESS
Date:
2018-05-09
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
GAA-ITEM: PERSONALIZING THE PREDICTION OF ANTI-THERAPEUTIC ANTIBODY RESPONSE IN POMPE DISEASE PATIENTS
Obligated Amount:
$324,980
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0

Trademarks

Serial Number:
97231957
Mark:
EPIVAX THERAPEUTICS
Status:
Registered. The registration date is used to determine when post-registration maintenance documents are due.
Mark Type:
Service Mark
Application Filing Date:
2022-01-21
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
EPIVAX THERAPEUTICS
USPTO Link:
View Trademark on United States Patent and Trademark Office Website

Goods And Services

For:
Research and development of vaccines and medicines; Pharmaceutical research and development; Vaccine research and development
First Use:
2021-02-26
International Classes:
042 - Primary Class
Class Status:
ACTIVE
Serial Number:
90383773
Mark:
PANDA
Status:
Registered. The registration date is used to determine when post-registration maintenance documents are due.
Mark Type:
Service Mark
Application Filing Date:
2020-12-15
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
PANDA
USPTO Link:
View Trademark on United States Patent and Trademark Office Website

Goods And Services

For:
Scientific and technical services, namely, analysis and testing of protein therapeutic sequences in the field of immunogenicity
First Use:
2017-10-20
International Classes:
042 - Primary Class
Class Status:
ACTIVE
For:
Health screening services in the field of immunogenicity; Providing medical information to scientists in the form of reports in the field of immunogenicity
First Use:
2017-10-20
International Classes:
044 - Primary Class
Class Status:
ACTIVE
Serial Number:
87294409
Mark:
EPIMATRIX
Status:
A Sections 8 and 15 combined declaration has been accepted and acknowledged.
Mark Type:
Service Mark
Application Filing Date:
2017-01-09
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
EPIMATRIX
USPTO Link:
View Trademark on United States Patent and Trademark Office Website

Goods And Services

For:
Research, development, engineering and testing services in the fields of proteins and T cell vaccines; Providing temporary use of non- downloadable software to predict the immunogenicity of protein therapeutics, to deimmunize proteins and to design T cell vaccines
First Use:
1998-05-20
International Classes:
042 - Primary Class
Class Status:
ACTIVE
Serial Number:
87293011
Mark:
PREDEFT
Status:
A Sections 8 and 15 combined declaration has been accepted and acknowledged.
Mark Type:
Service Mark
Application Filing Date:
2017-01-08
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
PREDEFT
USPTO Link:
View Trademark on United States Patent and Trademark Office Website

Goods And Services

For:
Scientific and technical services, namely, analysis and testing of protein therapeutic sequences in the field of immunogenicity
First Use:
2001-06-20
International Classes:
042 - Primary Class
Class Status:
ACTIVE
Serial Number:
85583859
Mark:
EPIVAX
Status:
The registration has been renewed.
Mark Type:
Service Mark
Application Filing Date:
2012-03-29
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
EPIVAX
USPTO Link:
View Trademark on United States Patent and Trademark Office Website

Goods And Services

For:
Scientific research consulting services in the field of bio-infomatics for the treatment of humans
First Use:
1998-05-20
International Classes:
042 - Primary Class
Class Status:
ACTIVE

Paycheck Protection Program

Jobs Reported:
29
Initial Approval Amount:
$447,000
Date Approved:
2020-04-04
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$562,000
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
$565,996.44
Servicing Lender:
Bank Rhode Island
Use of Proceeds:
Payroll: $562,000

Reviews Leave a review

This company hasn't received any reviews.

Related by address

188 VALLEY STREET SUITE 424, PROVIDENCE, RI, 02909, USA

GAIA Vaccine Foundation
Domestic Non-Profit Corporation
GAIA Vaccine Foundation, which currently Activ, has registered address 188 VALLEY STREET SUITE 424, PROVIDENCE, RI, 02909, USA.
EpiVax Therapeutics, Inc.
Foreign Corporation
EpiVax Therapeutics, Inc., which currently Activ, has registered address 188 VALLEY STREET SUITE 424, PROVIDENCE, RI, 02909, USA.
EpiVax, Inc.
Foreign Corporation
EpiVax, Inc., which currently Activ, has registered address 188 VALLEY STREET SUITE 424, PROVIDENCE, RI, 02909, USA.

Date of last update: 09 Jul 2025

Sources: Rhode Island Department of State

Privacy policy Policy
About us About us Business Directory
Contacts Contact us

© 2025 riorgs.com, Part of Big Data Integrated